Rigel Pharmaceuticals published the final data from its Phase 1/2 ARROW study of pralsetinib (Gavreto) in metastatic RET fusion-positive NSCLC in the Journal of Clinical Oncology. The report adds 42 months of additional follow-up to previously published results. The company said the therapy produced robust, durable responses with a manageable safety profile, emphasizing early biomarker testing. In the measurable-disease population (n=259), the overall response rate was 70%, including 7% complete responses. Rigel also reported three treatment-related deaths in treatment-naive patients in Asia (pneumonia, interstitial lung disease, and rhabdomyolysis) and said there were no new safety signals and no hypersensitivity reactions in patients with prior immunotherapy.